| 12473273 |
Quinoline compounds and compositions for inhibiting EZH2 |
Xuedong Dai, Michael Dore, Xiang-Ju Justin Gu, Li Nan Li, Sing Yeung Mak +8 more |
2025-11-18 |
|
| 12414952 |
Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
Zachary G. Brill, Amjad Ali, Jared N. Cumming, Duane DeMong, Qiaolin Deng +10 more |
2025-09-16 |
|
| 12371434 |
MLL1 inhibitors and anti-cancer agents |
Zhenting GAO, Haibing GUO, Ming Li, Chunliang Lu, Zhuming SUN +1 more |
2025-07-29 |
|
| 12291688 |
Silicon-containing compounds for lubricants |
Sheng Jiang, Ashutosh Gupta |
2025-05-06 |
|
| 12275729 |
Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Yongqi Deng, Abdelghani Achab, David Jonathan Bennett, Indu T. Bharathan, Xavier Fradera +8 more |
2025-04-15 |
|
| 12263171 |
7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Yonglian Zhang, Amjad Ali, Jared N. Cumming, Duane DeMong, Qiaolin Deng +10 more |
2025-04-01 |
|
| 12060357 |
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Matthew A. Larsen, Amjad Ali, Jared N. Cumming, Duane DeMong, Qiaolin Deng +11 more |
2024-08-13 |
$234,312,000 |
| 11319283 |
Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Meredeth A. McGowan, Abdelghani Achab, Xavier Fradera, Yongxin Han, Derun Li +6 more |
2022-05-03 |
$363,616,000 |
| 11312719 |
9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Matthew A. Larsen, Amjad Ali, Jared N. Cumming, Duane DeMong, Qiaolin Deng +11 more |
2022-04-26 |
$216,387,000 |
| 11111232 |
Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Catherine White, Abdelghani Achab, Indu T. Bharathan, Xavier Fradera, Yongxin Han +7 more |
2021-09-07 |
$168,031,000 |
| 11096930 |
Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase |
Phillip M. Cowley, Meredeth A. McGowan, Thomas J. Brown, Yongxin Han, Qinglin Pu +3 more |
2021-08-24 |
$126,043,000 |
| 11053243 |
Inhibitors of hepatitis C virus replication |
Craig A. Coburn, Steven W. Ludmerer, Hao Wu, Richard Soil, Bin Zhong +1 more |
2021-07-06 |
$119,175,000 |
| 11034661 |
Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors |
Liangqin Guo, Yongxin Han, Shuwen He, Joseph A. Kozlowski, Ravi Nargund +6 more |
2021-06-15 |
$253,758,000 |
| 10995085 |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig R. Gibeau +8 more |
2021-05-04 |
$204,878,000 |
| 10988487 |
Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Abdelghani Achab, Purakkattle Biju, Timothy A. Cernak, Yongqi Deng, Xavier Fradera +10 more |
2021-04-27 |
$169,438,000 |
| 10927086 |
Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Dane Clausen, Liangqin Guo, Yongxin Han, Shuwen He, Joseph A. Kozlowski +4 more |
2021-02-23 |
$566,829,000 |
| 10745364 |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John MacLean, Brian M. Andresen +9 more |
2020-08-18 |
$154,425,000 |
| 10689369 |
Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Mark E. Scott, B. Wesley Trotter +1 more |
2020-06-23 |
$115,870,000 |
| 10647705 |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors |
Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig R. Gibeau +8 more |
2020-05-12 |
$155,382,000 |
| 10584121 |
Heteroaryl substituted benzoic acids as RORgammaT inhibitors and uses thereof |
Hongjun Zhang, Kenneth J. Barr, Blair T. Lapointe, Hakan Gunaydin, B. Wesley Trotter |
2020-03-10 |
$341,287,000 |
| 10538497 |
Compounds as indoleamine 2,3-dioxygenase inhibitors |
Yongxin Han, Abdelghani Achab, Purakkattle Biju, Yongqi Deng, Xavier Fradera +9 more |
2020-01-21 |
$220,499,000 |
| 10344000 |
Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Danielle F. Molinari, Qinglin Pu +3 more |
2019-07-09 |
$88,734,000 |
| 10287272 |
Substituted indazole compounds as RORgammaT inhibitors and uses thereof |
Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Mark E. Scott, B. Wesley Trotter +1 more |
2019-05-14 |
$81,943,000 |
| 10221142 |
Substituted pyrazole compounds as RORgammaT inhibitors and uses thereof |
Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Nunzio Sciammetta, Benjamin Wesley Trotter +5 more |
2019-03-05 |
$69,271,000 |
| 10221146 |
Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
Thomas D. Aicher, Chad A. VanHuis, William D. Thomas, John MacLean, Brian M. Andresen +9 more |
2019-03-05 |
$69,271,000 |
